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Abstract
Background: The chronic course of pulmonary sarcoidosis can lead to lung dysfunction due to fibrosis, in which
the signalling pathways TGF-β/Smad and VEGF-A may play a key role.
Methods: We evaluated immunoexpression of TGF-β1, Smad2, 3, and 7, and VEGF-A in serum and bronchoalveolar
lavage (BAL) fluid of patients (n = 57) classified according to the presence of lung parenchymal involvement
(radiological stage I vs. II-III), acute vs. insidious onset, lung function test (LFT) results, calcium metabolism
parameters, percentage of BAL lymphocytes (BAL-L%), BAL CD4+/CD8+ ratio, age, and gender. Immunoexpression
analysis of proteins was performed by ELISA.
Results: The immunoexpression of all studied proteins were higher in serum than in BAL fluid of patients (p >0.05).
The serum levels of TGF-β1 (p = 0.03), Smad2 (p = 0.01), and VEGF-A (p = 0.0002) were significantly higher in
sarcoidosis patients compared to healthy controls. There were no differences within the sarcoidosis group between
patients with vs. without parenchymal involvement, acute vs. insidious onset, or patients with normal vs. abnormal
spirometry results. In patients with abnormal spirometry results a negative correlation was found between forced
vital capacity (FVC) % predicted value and TGF-β1 immunoexpression in BAL fluid, and positive correlations were
observed between the intensity of lung parenchymal changes estimated by high-resolution computed tomography
(HRCT scores) and Smad 2 level in serum.
Conclusions: TGF-β/Smad signalling pathway and VEGF-A participate in the pathogenesis of sarcoidosis. BAL TGF-
β1, and Smad 2 in serum seem to be promising biomarkers with negative prognostic value, but further studies are
required to confirmed our observations.
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Background
Sarcoidosis is a chronic inflammatory disorder of un-
known aetiology. The diagnosis is made based on a clin-
ical and radiological picture, and is usually confirmed by
the presence of non-caseating granulomas in involved
organs. In about 90 % of patients granulomas are present
in intrathoracic lymph nodes and/or lung parenchyma,
but extrapulmonary presentations are frequent [1, 2].
The prognosis is relatively good; in about 60 % of pa-
tients with a plethora of phenotypes the disease disap-
pears without any clinically significant remains.
However, in other patients the course may be chronic,
sometimes progressive, or recurrent. The most severe
complication is lung fibrosis, occurring in 10–15 % of
patients and leading to severe functional impairment,
disability, and sometimes to death. Among different
negative prognostic factors—lung interstitial disease,
lung function test abnormality (of both restrictive and
obstructive patterns), and severe impairment of calcium
homeostasis may be listed as examples, whereas acute
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disease onset and isolated intrathoracic lymph node en-
largement (radiological stage I) are considered good
prognostic markers [3]. A tremendous research effort
has been made to find a reliable biomarker that would
be useful to predict long-term prognosis in sarcoidosis
patients. Unfortunately, the results have been inconclu-
sive, and it may be difficult at the disease onset to antici-
pate which patients would be free of disease and which
would develop the progressive and fibrotic form in fu-
ture. The role of TGFβ and TGFβ signalling pathway el-
ements (SMADs) have been extensively studied in
animal models of lung fibrosis and in idiopathic lung fi-
brosis (IPF), and this particular pathway seems to be
critical in wound healing, scarring, and fibrosis in differ-
ent organs and different diseases [4–6]. VEGF is a major
contributor to angiogenesis and regulates several cell
functions via its receptors (VEGFRs). The angiostatic-
angiogenic axis (HIF-1a—VEGF—ING-4) may play a
role in the pathogenesis of experimental lung fibrosis
and IPF [7, 8]. Moreover, it was shown recently that
these two molecular pathways are closely interrelated.
For instance, in cultured human umbilical vein endothe-
lial cells (HUVEC) physiological concentrations of VEGF
attenuated TGF-β-related phosphorylation of Smad2/3
[9]. TGF-β1 has been shown to stimulate VEGF-A ex-
pression in human lung fibroblast via the Smad3 signal-
ling pathway, but it downregulates VEGF-D expression
through TGF-β receptor and JNK signalling pathway
[10]. Interestingly, the same authors found decreased ex-
pression of VEGF-D in lung tissue of IPF patients [10].
In a rat model of lung fibrosis treatment with adenoviral
delivery of VEGF resulted in reduced endothelial apop-
tosis, increased vascularisation, and decreased pulmon-
ary hypertension due to reduced remodelling, but
significantly worsened pulmonary fibrosis [7]. Therefore,
the net effect of VEGF on lung fibrosis may depend on
the isoform predominance, as well as the extent to
which it is embedded in a cytokine network.
In sarcoidosis data are scarce and even more ambigu-
ous. TGF-β1 concentration was increased in BAL fluid
of sarcoidosis patients, but only in those with impaired
lung function [11]. Contrary to this, polymorphic alleles
of TGF-β1, implicated in lower levels of protein produc-
tion, were associated with more severe disease presenta-
tion [12]. Other genetic studies indicate the role of
polymorphic variants of TGF-β3 (with presumed modu-
lating role on TGF-β1 activity) in sarcoidosis-related fi-
brotic lung disease [13], and a protective role of TGF-β2
SNP [14].
Smad proteins have not been studied in sarcoidosis
so far. Data on the role of VEGF in the pathogenesis
of sarcoidosis are also inconclusive. VEGF BAL con-
centrations were shown to be higher in IPF patients
in comparison to sarcoidosis in one study [15], but
higher than in IPF and hypersensitivity pneumonitis
in another [16]. A study on induced sputum showed
lower VEGF levels in sarcoidosis compared to healthy
controls, and lower sarcoidosis in stage III-IV com-
pared to stage I [17]. Contrary to this, in another
study both serum and BALF VEGF levels were in-
creased in sarcoidosis in comparison to controls [18].
This variability of results between different studies
may be related to the fact that VEGF is involved in
angiogenesis and lymphangiogenesis in the early
stages of sarcoid inflammation and is not directly in-
volved in fibrosis, so the results may be different de-
pending on the stage of the process, the phenotype
(acute vs. chronic), and the different representation of
such processes as formation of granuloma and scar-
ring in the same patient.
In view of the above, the following questions are in-
triguing to us: 1. Are the immunoexpressions of these
proteins different for sarcoidosis and healthy subjects
when measured in serum and BAL fluid 2?. What are
the relations between these proteins in serum and
BAL fluid? 3. Are there any differences within the
sarcoidosis group between patients with different
phenotypes, and in relation to selected prognostic
markers?
Methods
Study and control groups
A total of 57 patients with pulmonary sarcoidosis
were recruited into the study. Patients were admitted
to the Department of Pneumonology and Allergy of
Norbert Barlicki Memorial University Hospital No. 1
in Lodz during the years 2010–2014. The diagnosis
was made based on current guidelines [1]. For each
patient a consistent clinical and radiological picture of
sarcoidosis with the presence of non-caseating granu-
loma in tissue biopsy was confirmed. The diagnosis
was documented by EBUS-TBNA, bronchial mucosal
biopsy, transbronchial peripheral lung biopsy, video-
mediastinoscopy, or extrathoracic biopsy (skin, per-
ipheral lymph nodes). The biopsy was not obligatory
in patients with bilateral hilar lymph node enlarge-
ment, acute symptoms (Löfgren syndrome), and typ-
ical BAL results (increased percentage of lymphocytes
with CD + 4/CD + 8 > 3.5). In the whole sarcoidosis
group the diagnosis was confirmed by biopsy in 42
patients. Based on chest X-ray results, patients were
classified into the following radiological subgroups:
stage I (hilar lymph node enlargement without signs
of parenchymal involvement), stage II (signs of paren-
chymal involvement in addition to hilar lymph node
enlargement), stage III (parenchymal involvement
without visible hilar lymph node enlargement), and
stage IV (signs of irreversible extensive lung fibrosis).
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Independent comparison of patients with acute dis-
ease onset (Löfgren syndrome with arthritis, erythema
nodosum, elevated body temperature—with at least
two symptoms present) and patients with insidious
disease onset was made. The clinical and biological
characteristics of the study group are presented in
Table 1.
The control group for the study consisted of 23
healthy non-smokers (for concentration in BAL fluid)
referred for bronchoscopy due to chronic cough or un-
defined changes on chest X-ray and 20 healthy non-
smokers (for concentration genes in serum). The BAL
control group consisted of subjects who, after thorough
examination, were finally diagnosed either with idio-
pathic cough or as potentially healthy—when radio-
logical signs were defined as clinically insignificant
changes or artefacts.
All participants signed an individual consent form.
The study was approved by the Ethics Committee of the
Medical University of Lodz (RNN/141/10/KE).
Bronchoscopy and bronchoalveolar lavage fluid (BALF)
collection
Bronchoscopy was performed with a flexible broncho-
scope (Pentax Safe-3000A, Tokyo, Japan) according to
Polish Respiratory Society guidelines [19]. Patients op-
tionally received Midanium and atropine before the
examination; 2 % lidocaine was used as a topical anaes-
thetic. BAL fluid (BALF) was collected from the medial
lobe, by instillation and subsequent withdrawal of 4 x
50 ml of 0.9 % NaCl. The fluid recovery was 52.1 ±
1.2 %. The crude BALF was filtered through a nylon
gauze to clear the thick mucus and other contaminants,
and then it was centrifuged at 2500 rpm for 10 min at
room temperature. The supernatant was separated, fro-
zen, and stored at −80 °C.
Lung function tests
Spirometry was performed according to Polish Respira-
tory Society guidelines [20] with a computer-based spir-
ometer (MES-1000, Poland). Forced vital capacity (FVC)
and forced expiratory volume in 1 s (FEV1) were mea-
sured, and the Tiffenau index (FEV1/FVC) was calcu-
lated. Lung diffusion capacity for carbon monoxide was
measured in patients presenting radiological signs of
lung parenchymal disease only (stage II-IV) with a single
breath method (Lungtest 1000 SB, MES, Poland) accord-
ing to ATS/ERS standards [21]. The values were cor-
rected for the haemoglobin concentration (DLCOc). All
data (except the Tiffeneau index) were presented as the
percentage of predicted value.
Computed tomography
High-resolution, thin section CT (HRCT) scans of the
lungs were available for 20 patients (out of 27 patients
with stage II and III, 74 %). Sections of 1-mm collima-
tion were acquired at 10-mm intervals from the apex to
the dome of a diaphragm, at 120 kV, 200 mA, and a scan
time of 0.6 s. All scans were obtained at full inspiration,
and the images were obtained at a window level of −700
Hounsfield units and a window width of 900 Hounsfield
units. For estimation of the extent of parenchymal in-
volvement and hilar lymph node enlargement, the classi-
fication published by Drent et al. [22] was applied.
Briefly, the extent of bronchovascular bundle thickening,
parenchymal nodules, septal/non-septal lines, and paren-
chymal consolidation were estimated in a four-grade
scale, and the sum of points described parenchymal in-
volvement (total parenchymal score).
Table 1 Clinical and biological characteristics of the study group. Patients were grouped according to the absence/presence of lung
parenchymal changes on chest X-ray (stage I vs. stage II-III) and clinical phenotype (acute vs. insidious onset)
Stage I Stages II-III Acute onset Insidious onset
n = 30 n = 27 n = 29 n = 28
Gender 15 F 15 M 11 F 16 M 15 F 14 M 11 F 17 M
Age 38.63 ± 8.84 42.88 ± 11.64 37.29 ± 12.06 36.62 ± 7.12
FEV1 [% pred.] 94.75 ± 14.01 92.30 ± 15.33 96.81 ± 14.76 90.33 ± 13.93
FVC [% pred.] 106.10 ± 12.51 102.19 ± 15.32 108.62 ± 12.44 99.81 ± 14.23
FEV1/FVC 0.75 ± 0.07 0.74 ± 0.07 0.74 ± 0.07 0.74 ± 0.06
DLCOc [% pred.] - 93.25 ± 16.33 - 94.15 ± 17.58
BAL-L% 32.6 ± 16.74 28. 88 ± 17.10 36.48 ± 16.38 24.99 ± 15.90
BALF CD4+/CD8+ 7.60 ± 4.55 4.78 ± 4.12 8.39 ± 4.56 4.42 ± 3.68
Ca2+S [mmol/l] 2.43 ± 0.08 2.38 ± 0.23 2.39 ± 0.17 2.43 ± 0.15
Ca2+U [mmol/24 h] 5.15 ± 2.33 4.64 ± 2.96 4.27 ± 2.60 5.51 ± 2.67
Abbreviations: BALF, bronchoalveolar lavage fluid, BAL-L% % of BAL lymphocytes, CD cluster of differentiation, DLCOc lung diffusion capacity for carbon monoxide
corrected for haemoglobin concentration, FEV1 forced expiratory volume in first second of expiration, FVC forced vital capacity, pred predicted, S serum, U urine
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Serum collection
The blood was collected from a cubital vein and left at
37 °C until clot formation (about 30–45 min). Then it was
placed in a refrigerator at a temperature of 4 °C for several
hours (0.5–24 h) until the total organisation of the clot.
Next, the tube was centrifuged (1200 x g, 10 min, 4 °C),
and serum was separated from the clot carefully into new
sterile tubes, frozen, and stored at −20 °C.
Immunoexpression analysis
TGF-β1, Smad 2, Smad 3, Smad 7, and VEGF-A immu-
noexpression levels in serum and BAL supernatant were
assessed using the following: ELISA Kit for TGF-β1
ELISA Kit (650.010.096, Diaclone, Besancon Cedex,
France), Enzyme-linked Immunosorbent Assay Kit For
Mothers Against Decapentaplegic Homolog 2 (Smad 2)
(SEC124Hu Cloud-Clone Corp. Huston, TX), Enzyme-
linked Immunosorbent Assay Kit For Mothers Against
Decapentaplegic Homolog 3 (Smad 3) (SEC123Hu
Cloud-Clone Corp. Huston, TX), Enzyme-linked Im-
munosorbent Assay Kit For Mothers Against Decapenta-
plegic Homolog 7 (Smad 7) (SEA648Hu Cloud-Clone
Corp. Huston, TX), and Enzyme-linked Immunosorbent
Assay Kit For Vascular Endothelial Growth Factor A
(VEGF-A)—(SEA143Hu Cloud-Clone Corp. Huston,
TX). The intensity of the final colorimetric reaction in
proportion to the amount of protein bound was mea-
sured on a plate reader (ELx800, BioTek) at 450 nm.
The obtained results were calculated using a calibration
curve constructed from standard solutions of known
concentrations (0.001–10 ng/ml).
Statistical analysis
Kruskal–Wallis test, Mann–Whitney test, Neuman–
Keuls’ multiple comparison test, and Spearman’s rank
correlation were used to assess the correlation between
protein expression and classification of sarcoidosis based
on radiological examination (stages I vs. II-III), acute vs.
chronic disease onset, spirometric parameters, DLCOc,
serum Ca2+ concentration, Ca2+ loss in 24-hour urine
collection, the percentage of lymphocytes in BAL (BAL-
L%), the phenotype of BAL immune cells (CD4+/CD8+),
high-resolution computed tomography score, age, and
sex of patients. P < 0.05 was established as the level of
statistical significance. All calculations were performed
by StatSoft (Poland).
Results
Immunoexpression levels of the studied proteins (TGF-β1,
Smad 2, 3, 7, VEGF-A) in serum of sarcoidosis patients vs.
controls
Statistically significant differences between patients and
controls were observed for TGF-β1 (P = 0.03, U Mann-
Whitney test), Smad 2 (P = 0.01, U Mann–Whitney test)
and for VEGF-A (P = 0.0002, U Mann–Whitney test),
with higher immunoexpression levels in sarcoidosis pa-
tients (see Figs. 1, 2, and 3).
Immunoexpression levels of TGF-β1, Smad 2, 3, 7, and
VEGF-A in serum and BAL fluid of patients with
pulmonary sarcoidosis
In the serum of the studied patients the highest immu-
noexpression level was observed for TGF-β1 and lower
for VEGF-A regardless of the presence of parenchymal
involvement or clinical phenotype (acute onset vs. insidi-
ous onset). The lowest expression was found for Smad
proteins, with significant lower mean immunoexpression
value for Smad 7—see Table 2 for results.
Also, in the BAL supernatant of the studied patients
the highest mean immunoexpression level was observed
for TGF-β1 and the lowest for VEGF-A (see Table 2). In
BAL supernatant the concentration of Smad 2, 3, and 7
proteins were below the limit of detection (0.0054 ng/
ml, 0.061 ng/ml, and 0.058 ng/ml, respectively).
There were no correlations (Spearman’s rank correl-
ation test) between serum and BAL immunoexpression
of TGF-β1 and VEGF-A (not calculated for Smads due
to undetectable levels in BAL).
Immunoexpression of TGF-β1, Smad 2, 3, and 7, and
VEGF-A within sarcoidosis patients in relation to
parenchymal involvement, clinical phenotype, and lung
function test results
Statistically significant differences in immunoexpression
levels of the studied proteins between patients without
and with parenchymal involvement (stages I vs. II-III)
and between clinical phenotypes (acute vs. insidious on-
set), both in serum and in BAL fluid, were not found
(P > 0.05, U Mann–Whitney test).
Fig. 1 Box and whisker plots presenting statistically significant
differences between patients and controls for TGF-β1 (P = 0.03, U
Mann- Whitney test)
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Similarly, statistically significantly differences in immu-
noexpression levels of selected proteins in serum and
BAL fluid were not found between patients with abnor-
mal compared to normal spirometry or between patients
with restrictive or obstructive spirometric pattern and
normal spirometry (P > 0.05, U Mann–Whitney test).
Immunoexpression of TGF-β1, Smad 2, 3, and 7, and
VEGF-A within sarcoidosis patients in relation to patients’
gender and age
Higher expression of VEGF-A in the serum of men com-
pared to women was found in the subgroup of patients
with parenchymal involvement (P = 0.02, U Mann–Whit-
ney test).
The correlations between immunoexpression of the study
proteins and selected biochemical and immunological
markers and lung function parameters in serum and BAL
fluid
We found few correlations between lung function pa-
rameters, selected laboratory markers, and protein levels
in serum and BAL fluid of patients with pulmonary sar-
coidosis (Table 3).
The correlation between protein immunoexpression
levels and high-resolution computed tomography score
Spearman’s rank correlation coefficient revealed statisti-
cally significant positive correlations between Smad 2
level in serum and HRCT scores: HRCT score (paren-
chymal), HRCT (nodular abnormalities), HRCT (linear
abnormalities), HRCT (consolidation) (see Table 4).
Discussion
To sum up, we found that patients with sarcoidosis have
higher serum levels of TGF-β1, Smad 2, and VEGF-A
than control subjects. Such a difference was not found
in BAL fluid, which is striking taking into account the
known phenomenon of peripheral depletion of CD4
lymphocytes related to accelerated inflammatory reac-
tion at the site of granuloma formation, i.e. in the lung.
T regulatory cells (CD4 + CD25 + FOXP3+ and CD4 +
CD39+) may be involved because they incompletely con-
trol the inflammation of injured tissues but are powerful
enough to mediate peripheral anergy [23, 24]. In this
context, our findings speak against this commonly ac-
knowledged concept. It is possible, however, that periph-
eral anergy is related merely to the interplay between
Fig. 2 Box and whisker plots presenting statistically significant
differences between patients and controls for Smad 2 (P = 0.01, U
Mann–Whitney test)
Fig. 3 Box and whisker plots presenting statistically significant differences between patients and controls for VEGF-A (P = 0.0002, U
Mann–Whitney test)
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various subsets of lymphocytes, but different inflamma-
tory mediators are released from different cellular
sources (both tissue-settled and circulating inflammatory
cells) into the circulation. This is in line with the con-
cept of sarcoidosis as a systemic disease. The lack of cor-
relations between these proteins in peripheral blood and
BAL fluid seems to confirm that these processes are far
more complicated, and that the peripheral concentration
of these markers does not directly reflect their local pro-
duction at the site of inflammation. Similar conclusions
were also drawn by other authors, who found that per-
ipheral blood mononuclear cells (PBMNC) isolated from
sarcoidosis patients released higher amounts of various
cytokines involved in the pathogenesis of sarcoidosis
(such as IL-1β, TNF-α, IL-6, and GM-CSF), compared to
controls [25].
Also, locally the net production of TGF-β is not a re-
sult of the activity of one-cell type. It was shown, that
BAL fluid TGF-β concentration is not related to its pro-
duction by isolated and cultured alveolar macrophages
(AM) in vitro [11], and in vitro production of this cyto-
kine by both peripheral and BAL mononuclear cells is
not related to any in vivo radiological and functional dis-
ease parameter [25].
In our study we observed the highest detected levels in
both serum and BAL fluid for TGF-β, and the lowest for
VEGF-A. There were no differences between subgroups
of patients classified according to the presence or ab-
sence of parenchymal disease, or lung function tests
results. Only the negative correlations between BAL
TGF-β and FVC (only in patients with abnormal spir-
ometry) support previous data confirming the negative
prognostic value of this biomarker [11]. The lack of
clear-cut differences between patients with and without
the presence of acknowledged risk factors connected to
worse prognosis, such as parenchymal involvement and
functional impairment, may be a result of selection bias.
Our group of patients were randomly selected (all con-
secutive patients with confirmed diagnosis of sarcoidosis
diagnosed in our department) and consisted mainly of
patients with relatively good prognosis. More than 50 %
of patients did not show radiological signs of parenchy-
mal involvement, there were no patients with stage IV
disease, and no patients had severe lung dysfunction. Al-
though a positive correlation was found between urine
calcium loss and serum immunoexpression level of
TGF-β1, only few patients revealed impaired calcium
metabolism. Moreover, this is a “one time point” study,
and follow-up data on the prognosis are not available at
this stage.
TGF-β pathway may be involved in self-remitting dis-
ease, when early phase of inflammation, characterised
among others by accelerated TNF-α, IFN-γ, and IL-2
production, gradually expires and its activation may
Table 2 Immunoexpression (mean value, ng/ml) of all studied proteins (TGF-β1, Smad-2, −3, and −7, and VEGF-A) in serum and BAL
supernatant of patients with sarcoidosis
Immunoexpression
(mean value, ng/ml)
Serum Protein X-ray stage I X-ray stages II-III Acute onset Insidious onset
TGF-β1 3.58 (1.054–6.05) 3.40 (0.0625–6.728) 3.45 (0.0625–6.05) 3.53 (0.0625–6.728)
Smad2 1.07 (0.244–4.784) 0.89 (0.035–3.71) 0.958 (0.035–4.784) 1.029 (0.061–3.71)
Smad3 0.875 (0.061–9.187) 0.864 (0.061–6.846) 0.908 (0.061–9.186) 0.824 (0.061–6.846)
Smad7 0.131 (0.058–0.681) 0.278 (0.058–2.82) 0.126 (0.19–0.681) 0.278 (0.058–2.827)
VEGF-A 2.47 × 10−3 (0.55–8.25) 2.27 × 10−3 (0.55–10.28) 2.314 × 10−3 (0.55–8.25) 2.44 × 10−3 (0.55–10.28)
BAL fluid TGF-β1 0.064 (0.062–0.081) 0.075 (0.062–0.143) 0.06 (0.06–0.139) 0.07 (0.06–0.143)
Smad2 not detected not detected not detected not detected
Smad3 not detected not detected not detected not detected
Smad7 not detected not detected not detected not detected








Abbreviations: Smad, (homologs of the Drosophila protein “mothers against decapentaplegic” (MAD) and the C. elegans protein SMA), TGF transforming growth
factor, VEGF vascular endothelial growth factor
Table 3 Correlations between the immunoexpression levels of the studied proteins and lung function test parameters, and selected
laboratory markers in patients with pulmonary sarcoidosis
Biological material Parameter Protein Subgroup Rho value P value
Serum Ca2+U TGF-β1 Acute onset 0.494 0.0437
FEV1/FVC VEGF Parenchymal involvement −0.488 0.0113
BAL fluid FVC TGF-β1 Abnormal Spirometry −0.702 0.0234
Abbreviations: see Tables 1 and 2 legends
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herald disease remission. On the other hand, the TGF-β
pathway may be activated in progressive lung fibrosis.
Indeed, TGF-β/Smad signalling has been recognised as a
key mediator of fibrosis. Therefore, in our study we also
focused on Smad protein immunoexpression levels in
sarcoidosis patients. We confirmed that Smad 2 immu-
noexpression was significantly increased in serum (but
not in BAL fluid) of sarcoidosis patients as compared
with controls. It should be pointed out that the data for
Smad proteins in sarcoidosis are lacking, but it may be
presumed that the trends for Smad (Smad 2 and/or 3)
immunoexpression should follow that of TGF-β1. It has
been well documented that Smad 2 and 3 are key down-
stream mediators of TGF-β1 and their biological func-
tion is the regulation of fibrogenesis in response to
TGF-β1. However, Smad 2 and Smad 3 activation and/or
TGF-β responses may be altered in different human cell
types because of differences in binding of Smad 2 and 3
to adaptor proteins SARA (Smad anchor for receptor
activation). This mechanism may be responsible for the
divergence between Smad 2 and Smad 3 immunoexpres-
sion and activation. Furthermore, the differential activa-
tion of Smad 2 and Smad 3 can be connected with a
unique subset of protein interactions with the TGF-β re-
ceptor complex [26]. Indeed, in our study we did not
find mutual correlation between the immunoexpression
of these proteins, but we observed that serum Smad 2
immunoexpression was elevated in sarcoidosis patients.
Interestingly, in our study we observed a positive correl-
ation between HRCT scores and overexpression of Smad
2. Recently, similarly to our data, intensive immunoex-
pression of Smad 2/3 complex has been observed in an
animal model in dogs with IPF [27].
Taking into account that VEGF is a pleiotropic cyto-
kine and strong proangiogenic mediator, and additionally
that it is observed in the areas of granuloma formation
[18, 28], in our study we decided to assess the immu-
noexpression level in sarcoidosis patients. Granulomas
are prominent mainly in the early phase of the disease,
whereas in chronic disease they are replaced by fibrosis.
VEGF-A has also been shown to be involved in lung fi-
brosis. We confirmed that VEGF-A was increased in
serum (but not in BAL fluid) in patients, regardless of
clinical and radiological classification. Our results are in
contrast to those obtained by Porębska et al. [29], who
did not find differences in the level of immunoexpres-
sion between patients and healthy subjects in serum. In-
significant differences were obtained only in BALF [29].
Our results are inconclusive in this matter, showing in-
creased immunoexpression of VEGF-A in serum, but we
were not able to show any correlations with parenchy-
mal involvement and lung function test impairment.
Zielonka et al. [30] found negative correlation between
serum angiogenic activity of ILD patients and their lung
diffusion capacity. A comparison of VEGF-A concentra-
tion in BAL fluid retrieved from lung segments with
more and fewer intensive parenchymal changes revealed
higher concentrations of VEGF-A in more involved lung
areas [31]. In sarcoidosis, data on the involvement of
angiogenesis and angiostasis in different stages of disease
natural history are sometimes contradictory. The angio-
static microenvironment was described in severe sar-
coidosis patients by several authors [15].
Conclusions
It should be stressed that the up-regulation of VEGF-A
and TGF-β1 in sarcoidosis patients observed in our
study, as compared with healthy subjects, supports data
confirming the involvement of these proteins in the
pathogenesis of sarcoidosis. However, their usefulness as
markers in the clinical aspect is controversial and
requires further study, particularly when TGF-β seems
to be modulated via many specific cytoplasmic or
membrane-bound proteins (including Smad 2 and/or
Smad 3), which are under regulation of different post-
transcriptional and translational modifications. Our ob-
servations concerning increased Smad 2 immunoexpres-
sion level in patients, and its correlation with HRCT
indicates the potential significance of Smad 2—but not
Smad 3—in the clinical course of sarcoidosis. On the
other hand, the lack of mutual correlation between
Smad 2 and Smad 3 supports the thesis that Smad 2 and
Smad 3 may separately regulate different tissue-specific
activation of TGF-β1 via various mechanisms, which de-
termine fibrosis and immune response in the lungs.
Abbreviations
BAL: Bronchoalveolar lavage; BALF: BAL fluid; DLCO: Diffusion capacity for
carbon monoxide; EBUS-TBNA: Endobronchial ultrasonography guided
transbronchial needle aspiration; ELISA: Enzyme-linked immunosorbent assay;
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